Published online Nov 27, 2026. doi: 10.4254/wjh.125343
Revised: August 2, 2026
Accepted: October 20, 2026
Published online: November 27, 2026
Processing time: 137 Days and 22.9 Hours
Hepatitis B surface antigen (HBsAg) persistence hinders the achievement of a functional cure in patients with chronic hepatitis B. Strategies to suppress or eliminate HBsAg and break the host immune tolerance while restoring immune response become key components of immune therapy-directed clinical cure. Agents that target HBsAg include monoclonal antibodies, small interfering RNAs, antisense oligonucleotides, gene editing technologies, capsid assembly modulators, and therapeutic agents targeting secretion pathways. Immune checkpoint inhibitors and other immune-based clearance approaches are also included within this strategic framework. These agents target the HBsAg lifecycle and its source templates, including covalently closed circular DNA and integrated hepatitis B virus DNA in the host genome. This article reviews these strategies by synthesizing the latest information from preclinical studies and clinical trials, summarises their mechanisms and efficacy, discusses challenges and prospects for combinations, and aims to provide a scientific basis for chronic hepatitis B curative research.
Core Tip: Hepatitis B surface antigen persistence is the primary driver of immune tolerance in chronic hepatitis B. Strategies that reduce or eliminate hepatitis B surface antigen to break host immune tolerance and reinvigorate an immune response are emerging as promising therapeutic avenues for clinical cure. These therapeutic modalities include monoclonal antibodies, small interfering RNAs, antisense oligonucleotides, gene-editing technologies, capsid assembly modulators, agents targeting secretory pathways, and immune-based clearance strategies. Combination strategies have shown synergistic effects. Future clinical trial designs must prioritize identifying optimal combinations that maximize synergy while minimizing toxicity.